As this clinical-stage biotechnology company focused on developing treatments for complex rare diseases enters the home stretch of its Biologics License Application submission, the coming months will be critical and worth watching closely.
The company we are profiling today is Larimar Therapeutics Inc. (LRMR), and the investigational drug in focus is Nomlabofusp, being developed for Friedreich's ataxia.
For comments and feedback contact: editorial@rttnews.com
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.